Umbilical Cord Blood Mononuclear Cells
Burkitt Lymphoma
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02722668CT.gov UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Burkitt Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Umbilical Cord Blood Mononuclear Cells (this asset) | Masonic Cancer Center, University of Minnesota | P2 | B · 57 |
| Nivestim | Fred Hutchinson Cancer Center | P4 | BBB |
| Vincristine Sulfate | AIDS Malignancy Consortium | P2 | BBB |
| Vindesine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | AIDS Malignancy Consortium | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Cytarabine | AIDS Malignancy Consortium | P4 | BBB |
| Adriamycin | AIDS Malignancy Consortium | P4 | BBB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BBB |
+42 more in the Burkitt Lymphoma cohort
Other indications for Umbilical Cord Blood Mononuclear Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell And NK-Cell Neoplasm | — | P2 | B · 57 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 57 |
| Chronic Myeloid Leukemia | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Umbilical Cord Blood Mononuclear Cells in Burkitt Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/umbilical-cord-blood-mononuclear-cells-burkitt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →